More Evidence on Iron Repletion in Heart Failure with Reduced Ejection Fraction

It is reasonable to routinely screen for and treat iron deficiency with intravenous repletion in these patients.

Previous clinical trials have found some benefit to iron repletion with ferric carboxymaltose in patients with heart failure and reduced ejection fraction (HFrEF) and iron deficiency. Two recent studies — one reporting the principal results of a randomized trial and the other a post hoc analysis of a previously published trial — provide a broader perspective on this intervention.

The manufacturer-sponsored IRONMAN trial (NCT02642562) enrolled 1137 individuals with HFrEF (median age, 73 years; 26% women; median hemoglobin, 12.1 g/dL), recent hospitalization or elevated natriuretic peptides, and biochemical evidence of iron deficiency. Participants were randomized to receive usual care or open-label infusion of ferric derisomaltose, which can …

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)